UK out to make itself more attractive to drug developers

U.K. officials are shaking up their biomedical research industry in order to make the country a more attractive place for drug developers. A string of academic health science centers will combine academic medical research departments and teaching hospitals, copying a structure in the U.S. that has benefited researchers. And officials will highlight the trials that are being planned for new drugs, making it easier for developers to recruit patients for their studies. Pfizer had to pull out of four planned trials in the U.K. after it was unable to find a sufficient number of patients who fit the profile.

- read the report from the Financial Times

PLUS: U.K. officials have nailed down a big part of the funding needed for a new "laboratory of the future" that will cost close to $400 million to build. Report

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."